<DOC>
	<DOCNO>NCT01493843</DOCNO>
	<brief_summary>This multicenter , randomize , double-blind , placebo-controlled trial evaluate efficacy safety carboplatin/paclitaxel carboplatin/paclitaxel/bevacizumab without GDC-0941 patient previously untreated advanced recurrent non-small cell lung cancer ( NSCLC ) . Patients randomize receive 4 cycle carboplatin/paclitaxel either GDC-0941 placebo , ( patient non-squamous NSCLC ) without ( patient squamous NSCLC ) bevacizumab . Anticipated time study treatment disease progression intolerable toxicity occurs . Patients placebo arm disease progression may cross open-label active GDC-0941 .</brief_summary>
	<brief_title>Study Evaluating Safety Efficacy Carboplatin/Paclitaxel Carboplatin/Paclitaxel/Bevacizumab With Without GDC-0941 Patients With Previously Untreated Advanced Recurrent Non-small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Histologically document advanced ( Stage IV ) recurrent squamous ( Arms A B ) nonsquamous ( Arms C , D , E , F ) nonsmall cell lung cancer ( NSCLC ) Consent collection archival formalinfixed paraffinembedded ( FFPE ) block freshly cut unstained tumor slide archival tumor tissue newly collect tumor sample ECOG performance status 0 1 Disease measurable per RECIST v1.1 Adequate hematologic end organ function Use effective contraception NSCLC document EGFR mutation associate response EGFR inhibitor document fusion gene involve ALK gene Prior therapy ( include chemotherapy , antibody therapy , tyrosine kinase inhibitor , radiotherapy , immunotherapy , hormonal therapy , investigational therapy ) Day 1 Cycle 1 treatment advance ( Stage IV ) recurrent NSCLC Known CNS disease except treated brain metastasis Type I diabetes Type II diabetes require chronic therapy insulin Any disease , metabolic dysfunction , physical examination finding , clinical laboratory find give reasonable suspicion disease condition contraindicate use investigational drug may affect interpretation result render patient high risk treatment complication Medical condition would contraindicate bevacizumab therapy nonsquamous NSCLC</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>